These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33524442)

  • 1. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
    Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) polymerases: managing genome stability.
    Meyer-Ficca ML; Meyer RG; Jacobson EL; Jacobson MK
    Int J Biochem Cell Biol; 2005 May; 37(5):920-6. PubMed ID: 15743666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis.
    Min W; Cortes U; Herceg Z; Tong WM; Wang ZQ
    Carcinogenesis; 2010 Dec; 31(12):2058-65. PubMed ID: 20926829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
    Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
    Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribosyl)ation in carcinogenesis.
    Masutani M; Fujimori H
    Mol Aspects Med; 2013 Dec; 34(6):1202-16. PubMed ID: 23714734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
    Harrision D; Gravells P; Thompson R; Bryant HE
    Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
    Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
    Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M; Nakagama H; Sugimura T
    Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
    Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
    Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    Mehta P; Bothra SJ
    Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase.
    Grady SL; Hwang J; Vastag L; Rabinowitz JD; Shenk T
    J Virol; 2012 Aug; 86(15):8259-68. PubMed ID: 22623791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells.
    Li P; Zhu X; Qu H; Han Z; Yao X; Wei Y; Li B; Chen H
    Onco Targets Ther; 2024; 17():741-753. PubMed ID: 39258222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism.
    Davidovic L; Vodenicharov M; Affar EB; Poirier GG
    Exp Cell Res; 2001 Aug; 268(1):7-13. PubMed ID: 11461113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.